Researchers at The University of Queensland have identified a more efficient method of delivering peptide-based therapies for autoimmune diseases and allergies such as Multiple Sclerosis and Rheumatoid Arthritis. Their studies have found that in certain examples, the thiopalmitoylation of immunogenic peptides results in significantly greater efficacy, including an enhanced MHC Class II response, leading to significantly greater immune responses.  

• Licenceⁱ
• Commercial partner